Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BMS-1166 是 PD-1/PD-L1免疫检查点抑制剂。它促使 PD-L1 形成 PD-L1 同源二聚体,进而阻断其与 PD-1 的相互作用,其 IC50为 1.4 nM。它阻断了 PD-1/PD-L1 免疫检查点对 T 细胞活化的抑制作用。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 797 | 现货 | ||
2 mg | ¥ 1,160 | 现货 | ||
5 mg | ¥ 1,730 | 现货 | ||
10 mg | ¥ 2,970 | 现货 | ||
25 mg | ¥ 4,920 | 现货 | ||
50 mg | ¥ 6,870 | 现货 | ||
100 mg | ¥ 9,460 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,690 | 现货 |
产品描述 | BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor. |
靶点活性 | PD-1/PD-L1:1.4 nM |
体外活性 | BMS-1166 alleviate the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes. Moreover, the compounds were effective in attenuating the inhibitory effect of the cell surface-associated PD-L1. |
激酶实验 | Purified proteins in 10 mM Tris (pH 8.0) containing 20 mM NaCl, were concentrated to 5 mg/ml, mixed with the inhibitor in 1:3 molar ratio (protein:compound) and clarified by centrifugation at 15 000 × g for 10 min. Supernatant was used for screening using a sitting-drop vapor diffusion method. Diffraction-quality crystals were obtained at room temperature from 0.1 M Tris pH 8.5 containing 0.2 M magnesium chloride and 30% (w/v) PEG 4000 for the hPD-L1/BMS-1001 complex and from 0.01 M Tris pH 8.4 containing 0.28 M sodium chloride and 27% (w/v) PEG 4000 for hPD-L1/BMS-1166 complex. |
分子量 | 641.11 |
分子式 | C36H33ClN2O7 |
CAS No. | 1818314-88-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (194.97 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.5598 mL | 7.799 mL | 15.5979 mL | 38.9949 mL |
5 mM | 0.312 mL | 1.5598 mL | 3.1196 mL | 7.799 mL | |
10 mM | 0.156 mL | 0.7799 mL | 1.5598 mL | 3.8995 mL | |
20 mM | 0.078 mL | 0.3899 mL | 0.7799 mL | 1.9497 mL | |
50 mM | 0.0312 mL | 0.156 mL | 0.312 mL | 0.7799 mL | |
100 mM | 0.0156 mL | 0.078 mL | 0.156 mL | 0.3899 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
BMS-1166 1818314-88-3 Apoptosis Cell Cycle/Checkpoint Immunology/Inflammation PD-1/PD-L1 Inhibitor BMS1166 activation BMS 1166 immune cell interaction dimerization checkpoint inhibit inhibitor